Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

in Chicago April 25-30 and the American Society of Gene and Cell Therapy (ASGCT) in New Orleans May 13-17. The proof-of-concept studies demonstrate that Strand’s programmable mRNA genetic ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Based on his research data to date, he now wants to investigate further mRNA therapy candidates for liver-specific diseases as well as non-coding RNAs that could control the regeneration of liver ...

Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a ...

The biotech states its asset, developed on an mRNA lipid nanoparticle platform ... Vivet Therapeutics and Pfizer are developing a gene therapy called VTX-801, currently in a Phase I/II trial ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...